Nt4.zacks.com



Shire plc |(SHPG- NASDAQ) |$89.20 | |Shares per ADS: 3:1

Note: More details to come; changes are highlighted. Except where noted, and highlighted, no other section of this report has been updated.

Reason for Report: Flash Update: 2Q12 Earnings

Prev. Ed.: June 14, 2012; 1Q12 Earnings with new reports

Flash Update

Strong Quarter at Shire – August 1, 2012

Shire plc posted second-quarter 2012 earnings (excluding special items) of $1.68 per ADS, beating the Zacks Consensus Estimate of $1.52 per ADS. The reported quarter’s earnings were up 26% from the year-ago figure due to higher revenues.

Revenues increased 14% to $1.21 billion, above the Zacks Consensus Estimate of $1.19 billion driven by higher product sales.

Quarter in Detail

Product sales went up 16% to $1.15 billion. Products that performed well during the quarter include Vyvanse (up 43% to $266.2 million), Replagal (up 3% to $123.2 million), Vpriv (up 31% to $82.7 million) and Intuniv (up 16% to $69.1 million).

Firazyr sales were $31.7 million, up 58.5% from the previous quarter. Dermagraft, which was added to Shire’s portfolio following the Advanced BioHealing Inc. acquisition, generated revenues of $52.4 million in the quarter.

Adderall XR’s second-quarter sales decreased 9% to $133.9 million due to lower prescription demand and destocking of the drug. In June 2012, the US Food and Drug Administration (FDA) approved the abbreviated new drug application (ANDA) filed by Actavis for its generic version of Adderall XR. Actavis is in the process of being acquired by Watson Pharmaceuticals Inc.

The company has two authorized generic partners – Teva Pharmaceuticals and Impax Laboratories. Royalties decreased 11% to $56.3 million. The decrease in royalty revenue was primarily due to a fall in 3TC and Zeffix royalties (down 6% to $10.6 million) and Adderall XR (down 5% to $25.7 million).

Research & development (R&D) costs climbed 20% to $205.2 million. The increase was attributable to the company’s efforts to develop its pipeline. Selling, general & administrative (SG&A) expenses increased 5% to $409.6 million. The higher SG&A expenses were due to inclusion of Advanced BioHealing Inc.’s costs.

Outlook

For 2012, Shire expects revenues and earnings to exhibit double-digit growth. Product sales are expected to grow in the low-teens in 2012 (previous guidance: mid-teen range). Foreign exchange movements and generic competition for Adderall XR are expected to hamper product sales.

Royalty income, along with other revenue, is expected to decline 25% – 35% (previous guidance: 15% – 25%) due to lower royalties from Impax Lab. Post the approval of Actavis’ generic version of Adderall XR, Impax Lab is liable to pay significantly less royalties to Shire.

Gross margins are expected to be slightly lower than 2011. Shire expects 2012 combined R&D and SG&A expenses (adjusted) to increase in the range of 10% – 12% (previous guidance: 12% – 14%) on a year-over-year basis.

Details, other news update and broker comments will be provided in the next edition.

Portfolio Manager Executive Summary

Shire, a specialty biopharmaceutical company, aims at fulfilling the needs of specialist physicians. Shire focuses on a number of therapeutic areas, including attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) disorders.

Of the 16 firms covering the stock, 11 (68.8%) gave positive ratings, 5 (31.2%) gave neutral ratings and none rendered a negative rating on the stock.

Positive or equivalent outlook – (11/16 firms): The firms with a positive stance are encouraged by the wide array of products at Shire. The firms believe that the company is well positioned for further growth given its broad portfolio and lack of significant patent cliffs. The bullish firms are positive on Shire’s efforts to expand the Vyvanse label. They are also encouraged by Shire’s efforts to expand through acquisitions and partnership deals. Most bullish firms view Shire's HGT business as a strong growth driver going forward.

Neutral or equivalent outlook – (5/16 firms): The firms are encouraged by the wide range of products at Shire. However, they remain concerned about the performance of new products, which are yet to realize full potential. The firms are concerned about the growth of the Replagal and Vpriv franchise given that competitor, Sanofi, has sorted out its manufacturing issues. Moreover, the delay in the approval of the Lexington plant for Vpriv is also concerning. firms are concerned about the termination of the development Lialda for the diverticulitis indication and the withdrawal of Replagal’s marketing application in the US. Most neutral firms, however, believe that these challenges are already reflected in the stock price.

June 14, 2012

Overview

Shire based in Dublin, Ireland operates as a global specialty pharmaceutical company. Shire operates in three areas: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT) and Regenerative Medicine (RM). The HGT business includes Elaprase, Replagal, Vpriv and Firazyr. Other products include ADHD products such as Adderall XR, Vyvanse, Intuniv and Pentasa; and Lialda for ulcerative colitis. Additional information about the company is available at .

The firms identified the following factors for evaluating the investment merits of Shire:

|Key Positive Arguments |Key Negative Arguments |

|Shire’s rich and diverse product portfolio should continue to drive growth. |Generic threat that looms over many of Shire’s lead drugs has the potential |

| |to hamper revenues. |

|Shire’s HGT products boasts of long patent protection, given the fact that |The presence of strong competitors like Novartis, Lilly, and Johnson & |

|they treat life-threatening diseases, reimbursement for these products have |Johnson, as well as generic suppliers of Ritalin and Adderall characterizes |

|generally been readily accessible. |the ADHD market. Shire’s products face stiff competition from Sanofi’s |

| |Fabrazyme and Cerezyme, now that Sanofi has sorted out its manufacturing |

| |issues. |

| |One of the company’s key products of Shire, Vpriv received complete response|

| |letter (CRL) from the FDA for production at Shire's Lexington facility. The |

| |firms are concerned about the potential inventory shortage. |

Note: The company’s fiscal year coincides with the calendar year.

June 14, 2012

Long-Term Growth

Shire, a specialty biopharmaceutical company with on its ADHD, gastrointestinal (GI) diseases, HGT and RM business. Post acquisition, Advanced BioHealing Inc. assets have been incorporated into the RM segment.

Shire possesses a strong portfolio of ADHD drugs, Vyvanse, Adderall XR, Intuniv and Equasym. Vyvanse, the lead product at Shire, enjoys 17% of the US ADHD market share. The company is engaged in expanding the Vyvanse label for other indications including major depressive disorder, excessive daytime sleepiness, and negative symptoms of schizophrenia as well.

The competition in the ADHD US market increased significantly in 2011 with the launch of generic versions of Johnson & Johnson's Concerta and Novartis’ Ritalin. Moreover, a new drug, Kapvay, was launched by Japanese pharmaceutical company, Shionogi & Co., Ltd, in 2011. Meanwhile, Shire is facing patent challenges for Vyvanse.

Shire’s is focused on acquiring products in specialist markets with strong patent protection, market exclusivity and global rights. Shire recently acquired FerroKin BioSciences, Inc. and Pervasis Therapeutics are steps in this direction. The company’s HGT business continues to perform well.

June 14, 2012

Target Price/Valuation

|Rating Distribution |

|Positive |68.75%↑ |

|Neutral |31.25%↓ |

|Negative |0.00% |

|Avg. Target Price (ADS) |$111.79↓ |

|High |$130.00 |

|Low |$99.00↓ |

|No. of Analysts with Target price /Total |15/16 |

Risk to target price include generic competition and pipeline setbacks.

Recent Events

Revenues Rise at Shire – April 26, 2012

Shire’s first quarter 2012 earnings (excluding special items) of $1.48 per American Depositary Share were 20% above the year-ago earnings. The year-over-year increase was attributed to higher revenue in the reported quarter. The Zacks Consensus Estimate was $1.56 per share.

Revenues increased 21% to $1.17 billion, above the Zacks Consensus Estimate of $1.15 billion. Revenues were driven by higher product sales.

Quarter in Detail

Product sales went up 24% to $1.11 billion. Products that performed well during the quarter include Vyvanse (up 29% to $260 million), Replagal (up 28% to $134 million), Elaprase (up 21% to $126 million), Vpriv (up 22% to $72 million) and Intuniv (up 63% to $69 million).

Firazyr sales were $20 million, up from $15 million reported in the previous quarter. Dermagraft, which was added to Shire’s portfolio after the Advanced BioHealing Inc. acquisition, generated revenues of $49 million in the quarter.

Adderall XR first quarter sales remained flat year over year as an increase in prescription demand was offset by higher sales deductions. Sales deductions of Adderall XR are expected in the range of 60% – 65% of gross sales of the product in 2012.

Royalties decreased 24% to $56.3 million. The decrease in royalty revenue was primarily due to a 62% fall in 3TC and Zeffix royalties (combined $13.6 million) partially offset by an increase in Adderall XR (up 51% to $25.3 million) and Fosrenol (up 23% to $10.0 million) royalties.

Research & development (R&D) costs climbed 10% to $190.9 million. Selling, general & administrative (SG&A) expenses increased 25% to $440.8 million. The higher SG&A expenses reflected incorporation Advanced BioHealing Inc.’s costs.

Outlook

For 2012, Shire is anticipating revenues in low-teens and earnings growth. Product sales are expected to grow in the mid-teens range in 2012. Royalty income along with other revenue is expected to decline 15% – 25%.

Gross margins are expected to be slightly lower than 2011 due to the Advanced BioHealing Inc. acquisition. Shire expects 2012 combined R&D and SG&A expenses (adjusted) to increase in the range of 12% – 14% (previously guided: 10% – 12%) on a year-over-year basis.

Revenue

Revenue was $1.2 billion in 1Q12, up 21% y/y. Revenues were boosted by strong product sales.

Total revenues comprised product sales, royalties and other revenues.

Product sales went up 24% y/y to $1.1 billion. The rise was mainly attributable to the impressive performance of existing as well as new products.

Royalty revenue decreased 24% y/y to $56.3 million. The decrease in royalty revenue was primarily due a 62% fall in 3TC and Zeffix royalties.

Other revenue was $8.6 million in 1Q12 versus $9.3 million in 1Q11.

Outlook: For 2012, Shire is anticipating low double-teens revenue growth. Product sales are expected to deliver mid teens growth in 2012. Royalty income along with other revenue is expected to decline 15% – 25%.

Specific Products

Note: Recent significant developments changes are highlighted in bold.

TOTAL PRODUCTS (including Specialty Pharmaceuticals and Human Genetic Therapies (HGT))

SPECIALTY PHARMACEUTICALS

Total Specialty product sales (including ADHD, Gastrointestinal (GI) Franchise and General and other products revenue) were $706.7 million in 1Q12 versus $616.1 million in 4Q10, up 15% y/y.

Attention deficit hyperactive disorder (ADHD) Franchise

Adderall XR

Indication: Attention deficit hyperactive disorder (ADHD)

Product Life Cycle Status: Marketed

Safety Issues: Adderall XR has a black box warning on its label for safety concerns related to amphetamine abuse or misuse. Besides, it also warns of the risk of sudden death in patients with structural cardiac abnormalities.

Sales: Total revenue was $111.4 million in 1Q12, flat y/y. Increase in Adderall XR prescription demand was offset by higher sales deductions. Sales deductions of Adderall XR are expected in the range of 60% – 65% of gross sales of the product in 2012.

Generics: On November 1, 2010, Impax filed a suit against Shire claiming a breach of contract regarding the supply of the generic version of Adderall XR. Shire has been supplying Impax with the generic version of the ADHD drug since October 2009. Shire has filed a counterclaim against Impax. It is also entangled in a legal battle with Watson Pharma, which is also seeking to market generic versions of the drug in multiple doses before its market exclusivity expires in April 2019. In April 2011, Shire filed a case of patent infringement and breach of contract against Watson Pharma following the abbreviated new drug application (ANDA) filed by the latter with the Food and Drug Administration (FDA) for generic versions of 5, 10, 15, 20, 25 and 30 mg strengths of the drug. A hearing is scheduled for June 13, 2012.

Vyvanse (lisdexamfetamine dimesylate)

Indication: Attention deficit hyperactivity disorder (ADHD)

Product Life Cycle Status: Marketed in the US, Canada and Brazil

Importance: Physicians and consumers believe that Vyvanse is a next generation ADHD treatment that provides impressive efficacy, extended duration of action and lower abuse possibility compared with other ADHD medicines. On November 15, 2010, the FDA cleared Vyvanse for treating ADHD in adolescents aged between 13 to 17 years.

Sales: Total revenue was $260 million in 1Q12, up 29% y/y. Strong demand of the drug in the US contributed to the increase. Vyvanse sales are expected to reach $1 billion in 2012.

Partnership terminated. During 3Q10, Shire terminated its co-promotion agreement with GlaxoSmithKline for Vyvanse. Per the agreement, Shire did not have to make any payments to Glaxo as the threshold sales levels were not reached.

Additional Studies: On October 21, 2011 Shire announced positive top line results from the first European phase III study of once-daily Vyvanse in children and adolescents aged 6 to 17 years with ADHD.

Additional Indications: On December 8, 2011, Shire announced encouraging results from a phase II study, which evaluated Vyvanse as an adjunctive treatment in patients suffering from major depressive disorder (MDD) who failed to respond adequately to the prior treatments for the disease. Shire has initiated phase III studies for the drug as an adjunctive therapy to primary MDD treatments.

On April 26, 2012, Shire reported positive data from a phase II study which evaluated Vyvanse in adults with binge eating disorder. Vyvanse is also being evaluated for treating the negative symptoms of schizophrenia patients. The company is planning to initiate a phase III study in 2012 for both the indications.

The company is also evaluating the drug for excessive daytime sleepiness (EDS). In January 2011, Shire announced results from a study evaluating Vyvanse in patients suffering from EDS. The study did not reveal any difference between Vyvanse (50 mg) and Cephalon’s Nuvigil. The company is planning to initiate a phase III study in 2012.

Generics: In July 2011, Shire announced that it has filed a patent infringement case against Sandoz, Inc. -- the generic arm of Novartis and Amneal Pharmaceuticals who are looking to market generic versions of Vyvanse at all doses. The marketing exclusivity for Vyvanse expired in February 2012, under the Hatch-Waxman Act. By filing patent infringement lawsuits Shire has ensured a 30-month stay by the FDA. Consequently, the US regulatory body cannot clear the ANDAs before August 23, 2014 or until a court rules the patents as invalid or not infringed, whichever happens earlier. In July 2011, Shire announced that it has filed similar patent infringement cases against Watson Pharma and Roxane Laboratories who too are looking to market generic versions of Vyvanse at all doses.

Equasym IR and Equasym XL

Indication: Attention deficit hyperactivity disorder (ADHD)

Product Life Cycle Status: Equasym XL is marketed in many countries outside the US, Canada, and Barbados and Equasym IR is marketed in some countries outside the US.

Partners: Shire acquired the worldwide rights to Equasym IR and XL (methylphenidate hydrochloride) (excluding the US, Canada and Barbados) from UCB in February 2009.

Sales: Total revenue was $7.2 million in 1Q12, up 57% y/y.

Intuniv (guanfacine)

Indication: Approved for treatment of ADHD in children aged between 6 and17 years in the US

Product Life Cycle Status: Intuniv is undergoing phase III studies in the EU for treating ADHD in children aged between 6 to 17 years.

Importance: Intuniv is a non-scheduled and non-stimulant ADHD drug. Intuniv, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD

Sales: Total revenue was $68.5 million in 1Q12, up 63% due to increased demand in the US.

Competitors: The drug faces competition from Eli Lilly’s Strattera.

Generics: On November 1, 2010, Shire announced the receipt of a Paragraph IV Notice Letter from Impax Laboratories, Inc. regarding the filing of an ANDA for a generic version of Shire’s 4 mg Intuniv. Shire received similar communication from Watson Pharmaceuticals in October 2010. In December 2010, Shire challenged the applications. No trial date has been set yet.

During 1Q10, Shire received Paragraph IV Notice Letters from Teva, Actavis, and Anchen Pharmaceuticals Inc., advising the filing of ANDAs for generic versions of Shire’s 1 mg, 2 mg, 3 mg, and 4 mg, Intuniv. A trial is expected to commence on September 17, 2012.

During 1Q11, Shire was notified that Mylan and Sandoz have filed ANDAs seeking to market the generic versions of Intuniv (4 mg). Shire has challenged both applications thus triggering 30-month stays on the ANDAs.

Gastrointestinal (GI) Franchise

Pentasa

Indication: Mild-to-moderately active ulcerative colitis (UC)

Product Life Cycle Status: Marketed

Sales: Total revenue was $65.8 million in 1Q12, up 2% y/y.

Lialda/Mezavant (Ex US - Mezavant XL)

Indication: Ulcerative colitis (UC), maintenance therapy for the remission of UC

Product Life Cycle Status: Marketed

Sales: Total revenue was $90.0 million in 1Q12, up 3% y/y. Increased demand led by favorable pricing contributed to the increase.

Additional Indications: Shire has discontinued the development of Lialda for patients with diverticulitis, a colonic disease during 1Q12 after a phase III study failed to met the primary endpoint.

General and Other specialty Products

Fosrenol (lanthanum carbonate)

Indication: Hyperphosphatemia in end stage renal disease (ESRD)

Product Life Cycle Status: Marketed

Regulatory status: On March 8, 2012, Shire received approval for its oral powder formulation of Fosrenol through the European Decentralised Procedure.

Partners: Fosrenol is marketed in Japan through Shire's strategic alliance partner; Bayer Yakuhin Ltd. Shire receives a double-digit royalty on Bayer's net sales of Fosrenol.

Sales: Total revenue was $45.5 million in 1Q12, up 10% y/y. The increase in product sales was attributable to increase in market share in the US.

Competitors: Fosrenol’s main competitors are Fresenius’ PhosLo and Sanofi’s Renagel.

Generics: Mylan Pharmaceuticals, Inc. in collaboration with Matrix Laboratories, Inc., Natco Pharma Limited and Alkem Laboratories Ltd. have filed ANDAs seeking to market generic versions of the drug. Shire has challenged the applications thus triggering 30-month stays on the ANDAs.

Agrylin/Xagrid

Indication: Thrombocythernia

Product Life Cycle Status: Marketed

Sales: Total revenue was $23.2 million in 1Q12, up 2% y/y.

HUMAN GENETIC THERAPIES (HGT) Franchise

Total HGT product sales (including revenue from Elaprase, Replagal, Vpriv and Firazyr) were $351.4 million in 1Q12, up 29% y/y.

Elaprase (idursulfase)

Indication: Hunter syndrome

Product Life Cycle Status: Marketed

Importance: The drug has seven-year orphan drug market exclusivity in the US and the EU. Elaprase is the first enzyme replacement therapy approved for people suffering from Hunter syndrome. Hunter syndrome is a rare X-linked genetic disease caused by a deficiency in I2S (iduronate-2-sulfatase).

Sales: Total revenue from the drug was $125.6 million in 1Q12, up 21% y/y. Growth was driven by increased volumes across all regions.

Replagal (agalsidase alfa)

Indication: Fabry disease

Product Life Cycle Status: Marketed outside the US

Importance: The product is at present approved for marketing and commercial distribution in multiple countries outside the US.

Sales: Total revenue was $134.4 million in 1Q12, up 28% y/y. The rise was attributable to increased demand resulting from patients switching to Replagal treatment coupled with the treatment of new patients. On March 14, 2012, Shire announced that it has withdrawn its marketing application for Replagal in the US for Fabry disease. Shire had submitted the Biologics License Application (BLA) for Replagal with the FDA in November 2011.

.

Patent Litigation: In April 2010, Mt. Sinai School of Medicine of New York University filed two lawsuits in Sweden and Germany, stating that Replagal infringes its patents. In May 2012, the company and Mt. Sinai decided to settle the dispute and discontinue the legal proceedings. A few firms are positive about this development.

Competitors: Replagal faces stiff competition from Sanofi’s Fabrazyme.

Vpriv (velaglucerase alfa/ GA-GCB)

Indication: A human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease in pediatric and adult patients.

Product Life Cycle Status: Marketed

Sales: Total revenue from the drug was $71.7 million in 1Q12, up 22% y/y. The rise was attributable to increased demand resulting from patients switching from Cerezyme coupled with new patient additions.

Competitors: Vpriv faces competition from Sanofi’s Cerezyme and Protalix/Pfizer’s Elelyso. Some firms believe that the impact on Vpriv’s sales due to entry of Elelyso will be limited.

During the 1Q12 results, the company said the FDA has issued a complete response letter (CRL) for Vpriv production at Shire's Lexington facility. Shire is continuing to manufacture the product at Alewife, which is approved by the FDA. The company said that it has sufficient capacity to meet the Vpriv demand in 2012, however the approval of the Lexington unit will enable it to normalize the inventory level. Some firms believe that the CRL issue will be resolved in 6 months.

Firazyr (icatibant)

Indication: Firazyr is a peptide-based therapeutic for hereditary angioedema (HAE), a rare genetic disease characterized by acute swelling of the hands, feet, face and larynx.

Product Life Cycle Status: Marketed

Importance: Firazyr is the first product for HAE in Europe in 30 years and has orphan exclusivity in the EU until 2018. Firazyr also has orphan drug status in the US.

Sales: Total revenue was $19.7 million in 1Q12, up 272% y/y. The increase was primarily driven by sales in the US post launch in 4Q11.

Pipeline Candidates

SPD535 (a novel platelet reducing agent)

Indication: Arteriovenous grafts in hemodialysis patients

Product Life Cycle Status: Phase I studies demonstrating positive proof-of-principle are complete. Currently the candidate is being evaluated in additional phase I studies to support progression to a phase II proof-of-concept program for the prevention of thrombotic complications associated with arteriovenous access in patients suffering from hemodialysis.

metazym/HGT-1110: The company acquired HGT-1111 (arylsulfatase –A), an enzyme replacement therapy (ERT) in April 2008. The candidate is currently undergoing pre-clinical studies for metachromatic leukodystrophy (MLD). Metachromatic leukodystrophy is a serious, life-limiting disease in which patients experience progressive irreversible neurological damage.

HGT-1410: HGT-1410 is a potential therapy for treating Sanfilippo disease, which is caused by a deficiency of the enzyme heparan N-sulfatase. The candidate has been granted orphan drug designation in the US and EU. The candidate is currently undergoing a phase I/II study.

HGT-2310: The company is developing HGT-2310 as an enzyme replacement therapy (ERT). The candidate is delivered intrathecally for Hunter syndrome in patients suffering from central nervous system (CNS) symptoms. The candidate, which enjoys orphan drug status in the US, is undergoing a phase I/II study.

Acquisitions, collaborations

On April 19, 2012, Shire acquired almost all the assets of Pervasis Therapeutics. As per the terms of the agreement, Shire made an upfront payment of $2.5 million and regulatory, development and commercial milestones upto $169.5 million will be made in due course.

This acquisition adds Vascugel developed using an acute vascular repair technology for improving hemodialysis access for patients with end-stage renal disease (ESRD) to Shire’s pipeline. The candidate has orphan drug designation in both US and Europe and is currently in phase II studies.

On March 15, 2012, Shire entered into an agreement to acquire FerroKin BioSciences, Inc. Per the terms of the agreement, Shire made an upfront payment of $94.5 million and will make up to $225 million as regulatory, development and commercial milestones upon the achievement of certain pre-specified conditions.

This acquisition adds SPD 602 for treatment of iron overload following numerous blood transfusions to Shire’s pipeline.

On February 1, 2012 Shire and Sangamo BioSciences, Inc. entered into a collaboration and license agreement for the development of products for hemophilia and other monogenic diseases. These products will be developed using Sangamo’s zinc finger DNA-binding protein (”ZFP) technology.

As per the agreement, Shire will get exclusive global rights to ZFP therapeutics designed to target 4 genes for investigating curative therapies for hemophilia A and B. Shire also gets the right to designate 3 additional gene targets. While Sangamo will undertake all responsibilities till the submission of an Investigational New Drug (IND) application or European Clinical Trial Application (CTA), Shire will reimburse Sangamo’s program-related costs (both external and internal)

Margins

1Q12 operating income (excluding special items) was $362 million, up 18% y/y. The increase was driven by higher revenues in 1Q12. However, rate of increase in total operating expenses were slightly higher than rate of increase in total revenues.

R&D expenditure on an adjusted basis climbed 17% y/y to $190.9 million, due to investments in development programs including HGT 2310 and new indications for Vyvanse.

SG&A expenses (adjusted) climbed 40% y/y to $440.8 million. The rise was attributable to an increase in expenses related to existing products, product launches and international expansion.

Outlook: Gross margins in 2012 are expected to be slightly lower than 2011 due to the Advanced BioHealing Inc. acquisition. Shire expects 2012 combined R&D and SG&A expenses (adjusted) to increase in the range of 12% – 14% y/y (previously guided: 10% – 12%).

Earnings per American Depositary Share

Adjusted earnings per ADS were $1.48 in 1Q12, up 20% y/y, driven by higher revenues.

During the 1Q12 conference call the company said it is expecting to see good earnings growth in FY12.

– The Online Stock Research Community

Discover what other investors are saying about Shire Plc (SHPG) at :

SHPG profile on

|Analyst |Lopamudra Bhattacharya |

|Last Updated By |Lopamudra Bhattacharya |

|Copy Editor |Maharathi Basu |

|Content Editor |Maharathi Basu |

|Lead Analyst |Maharathi Basu |

|QCA |Arpita Dutt |

|Reason for Update |Flash |

-----------------------

[pic]

!017íÛɲ›„mVE5(5hê9Î5?CJOJ[?]QJ[?]^J[?]h¨$Ìhê9Î5?CJOJ[?]QJ[?]^J[?] hjw#h`q5?B*[pic]CJaJph,hXh-h`q5?B*[pic]CJOJ[?]QJ[?]^J[?]aJph,hXh-hXh-5?B*[pic]CJOJ[?]QJ[?]^J[?]aJph,hÀÒh3›5?B*[pic]CJOJ[?]QJ[?]^J[?]aJph,h uth`q5?B*[pic]CJOJ[?]QJ[?]^J[?]aJph,h uth¨$Ì5?B*[pic]CJOJ[?]QJ[?]^J[?]aJph#h¨$Ìh`q5?CJ(OJ[?]QJ[?]^J[?]aJ(#h¨$ÌhÊ;½5?CJ(OJ[?]QJZacks Investment Research Page 2

August 2, 2012

© Copyright 2012, Zacks Investment Research. All Rights Reserved

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download